New asthma drug tezepelumab tested in everyday clinics

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female outpatients aged 12 years or older at the time of signing the informed consent/assent form. * Patients who have been prescribed but not yet initiated treatment with tezepelumab according to the label and local market reimbursement criteria. * Diagnosis of asthma for at least 52 weeks prior to enrolment date and symptoms confirmed by the Investigator not to be due to alternative diagnoses. * Receipt of at least one prescription of high-dose Inhaled Corticosteroids (ICS) (according to the Global Initiative for Asthma 2024) during the 52 weeks prior to enrolment date. * Use of additional asthma maintenance controller medication(s) in addition to ICS either as free- or fixed-drug combination for at least 52 weeks prior to enrolment date. * Documented history of at least 1 asthma exacerbation during the 52 weeks prior to enrolment date. * Asthma Control Questionnaire (ACQ-6) score ≥1.5 (indicating inadequate asthma symptom control) at enrolment. * Availability of at least one Blood Eosinophil Count (BEC) measurement (in medical records) in the 52-week period prior to enrolment date. * Availability of participants' medical records for asthma exacerbations and unscheduled Health Care Resource Utilization (HCRU) for the 52 weeks prior to enrolment date. * Patients are able to understand and complete the Patient-Reported Outcome (PROs). * Provision of signed and dated written informed consent/assent (as applicable). Exclusion Criteria: * Any contraindication to tezepelumab as per the approved product label or in the opinion of the Investigator. * Concurrent or recent (\<30 days before the index date) treatment with biologics for asthma, with the exception of stable allergen immunotherapy (defined as a stable dose and regimen at the time of enrolment). * Participation in an observational study that might, in the Investigator's opinion, influence the assessment for the current study, or participation in an interventional clinical trial in the last 3 months. * Currently pregnant (or intention to become pregnant) or lactating women.